Sarepta Therapeutics shares are trading higher after Raymond James reinstated an Outperform rating on the stock and announced a price target of $150.
Portfolio Pulse from Benzinga Newsdesk
Sarepta Therapeutics shares rose following Raymond James' reinstatement of an Outperform rating and a price target of $150.
October 10, 2024 | 4:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sarepta Therapeutics shares increased after Raymond James reinstated an Outperform rating and set a price target of $150.
The Outperform rating and a specific price target of $150 from a reputable firm like Raymond James is likely to boost investor confidence, leading to a positive short-term impact on Sarepta's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100